PMID- 16115932
OWN - NLM
STAT- MEDLINE
DCOM- 20051221
LR  - 20220317
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 11
IP  - 16
DP  - 2005 Aug 15
TI  - Immunologic evaluation of personalized peptide vaccination for patients with 
      advanced malignant glioma.
PG  - 5900-11
AB  - PURPOSE: The primary goal of this phase I study was to assess the safety and 
      immunologic responses of personalized peptide vaccination for patients with 
      advanced malignant glioma. EXPERIMENTAL DESIGN: Twenty-five patients with 
      advanced malignant glioma (8 grade 3 and 17 grade 4 gliomas) were evaluated in a 
      phase I clinical study of a personalized peptide vaccination. For personalized 
      peptide vaccination, prevaccination peripheral blood mononuclear cells and plasma 
      were provided to examine cellular and humoral responses to 25 or 23 peptides in 
      HLA-A24+ or HLA-A2+ patients, respectively; then, only the reactive peptides 
      (maximum of four) were used for in vivo administration. RESULTS: The protocols 
      were well tolerated with local redness and swelling at the injection site in most 
      cases. Twenty-one patients received more than six vaccinations and were evaluated 
      for both immunologic and clinical responses. Increases in cellular or humoral 
      responses specific to at least one of the vaccinated peptides were observed in 
      the postvaccination (sixth) samples from 14 or 11 of 21 patients, respectively. 
      More importantly, significant levels of peptide-specific IgG were detected in the 
      postvaccination tumor cavity or spinal fluid of all of the tested patients who 
      showed favorable clinical responses. Clinical responses were 5 partial responses, 
      8 cases of stable disease, and 8 cases of progressive disease. The median overall 
      survival for patients with recurrent glioblastoma multiforme in this study (n = 
      17) was 622 days. CONCLUSIONS: Personalized peptide vaccinations were recommended 
      for the further clinical study to malignant glioma patients.
FAU - Yajima, Naoki
AU  - Yajima N
AD  - Department of Neurosurgery, Brain Research Institute, Niigata University, 
      Niigata, Japan.
FAU - Yamanaka, Ryuya
AU  - Yamanaka R
FAU - Mine, Takashi
AU  - Mine T
FAU - Tsuchiya, Naoto
AU  - Tsuchiya N
FAU - Homma, Jumpei
AU  - Homma J
FAU - Sano, Masakazu
AU  - Sano M
FAU - Kuramoto, Terukazu
AU  - Kuramoto T
FAU - Obata, Yayoi
AU  - Obata Y
FAU - Komatsu, Nobukazu
AU  - Komatsu N
FAU - Arima, Yoshimi
AU  - Arima Y
FAU - Yamada, Akira
AU  - Yamada A
FAU - Shigemori, Minoru
AU  - Shigemori M
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Tanaka, Ryuichi
AU  - Tanaka R
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Peptides)
RN  - 0 (RNA, Messenger)
SB  - IM
CIN - Clin Cancer Res. 2005 Aug 15;11(16):5663-4. PMID: 16115899
MH  - Adult
MH  - Aged
MH  - Antigens, Neoplasm/genetics
MH  - Brain Neoplasms/drug therapy/genetics/*immunology
MH  - Cancer Vaccines/*immunology/therapeutic use
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/immunology
MH  - Glioma/drug therapy/genetics/*immunology
MH  - HLA-A Antigens/immunology
MH  - HLA-A2 Antigen/immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Immunoglobulin G/blood/cerebrospinal fluid
MH  - Leukocytes, Mononuclear/immunology
MH  - Male
MH  - Middle Aged
MH  - Peptides/*immunology/therapeutic use
MH  - RNA, Messenger/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Analysis
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Treatment Outcome
EDAT- 2005/08/24 09:00
MHDA- 2005/12/22 09:00
CRDT- 2005/08/24 09:00
PHST- 2005/08/24 09:00 [pubmed]
PHST- 2005/12/22 09:00 [medline]
PHST- 2005/08/24 09:00 [entrez]
AID - 11/16/5900 [pii]
AID - 10.1158/1078-0432.CCR-05-0559 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2005 Aug 15;11(16):5900-11. doi: 10.1158/1078-0432.CCR-05-0559.